MIRA Pharmaceuticals, Inc.
MIRA
$0.78
$0.034.01%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -61.18% | 238.00% | -10.84% | -5.95% | 48.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -38.87% | 138.94% | -36.73% | -10.67% | 2.09% |
| Operating Income | 38.87% | -138.94% | 36.73% | 10.67% | -2.09% |
| Income Before Tax | 35.52% | -149.34% | 44.34% | 9.08% | -3.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 35.52% | -149.34% | 44.34% | 9.08% | -3.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.52% | -149.34% | 44.34% | 9.08% | -3.84% |
| EBIT | 38.87% | -138.94% | 36.73% | 10.67% | -2.09% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 74.44% | -1.17% | -768.29% | 20.89% | 7.75% |
| Normalized Basic EPS | 74.48% | 2.43% | 49.76% | 20.84% | 7.71% |
| EPS Diluted | 74.44% | -1.17% | -768.29% | 20.89% | 7.75% |
| Normalized Diluted EPS | 74.48% | 2.43% | 49.76% | 20.84% | 7.71% |
| Average Basic Shares Outstanding | 151.97% | 146.50% | 27.89% | 14.92% | 12.61% |
| Average Diluted Shares Outstanding | 151.97% | 146.50% | 27.89% | 14.92% | 12.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |